Zymeworks (NASDAQ:ZYME) Price Target Raised to $56.00

Zymeworks (NASDAQ:ZYME) had its target price raised by HC Wainwright from $55.00 to $56.00 in a research note published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Zymeworks’ Q4 2026 earnings at $0.05 EPS, FY2026 earnings at $1.19 EPS, Q1 2027 earnings at $0.64 EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at $0.33 EPS, Q4 2027 earnings at ($0.78) EPS and FY2027 earnings at ($0.39) EPS.

A number of other equities research analysts have also recently commented on ZYME. Truist Financial upped their target price on shares of Zymeworks from $34.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, October 27th. TD Cowen began coverage on Zymeworks in a research report on Tuesday, September 29th. They set a “buy” rating and a $34.00 target price on the stock. B. Riley Financial reiterated a “buy” rating and set a $44.00 price target (up from $40.00) on shares of Zymeworks in a research report on Monday, August 10th. JPMorgan Chase & Co. lifted their target price on shares of Zymeworks from $31.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Finally, Wolfe Research initiated coverage on Zymeworks in a report on Thursday, September 17th. They issued an “outperform” rating on the stock. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zymeworks currently has an average rating of “Moderate Buy” and an average target price of $42.67.

Zymeworks Trading Down 8.9%

Shares of NASDAQ:ZYME opened at $26.47 on Tuesday. The business has a 50-day moving average price of $27.39 and a 200 day moving average price of $25.46. Zymeworks has a 12-month low of $18.20 and a 12-month high of $31.97. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of 50.90 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME) last issued its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, topping the consensus estimate of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The firm had revenue of $512.92 million for the quarter, compared to analyst estimates of $227.40 million. During the same period in the prior year, the business posted ($0.26) EPS. The business’s revenue for the quarter was up 828.7% compared to the same quarter last year. As a group, equities research analysts predict that Zymeworks will post 1.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Zymeworks news, EVP Adam Schayowitz sold 13,832 shares of the business’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $25.85, for a total value of $357,557.20. Following the sale, the executive vice president owned 23,205 shares in the company, valued at approximately $599,849.25. The trade was a 37.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 37.73% of the company’s stock.

Institutional Investors Weigh In On Zymeworks

Institutional investors have recently made changes to their positions in the company. Fisher Asset Management LLC boosted its stake in Zymeworks by 759.9% in the third quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock valued at $16,122,000 after buying an additional 537,837 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Zymeworks by 104.7% during the third quarter. Russell Investments Group Ltd. now owns 97,994 shares of the company’s stock worth $2,596,000 after acquiring an additional 50,127 shares during the last quarter. Calamos Advisors LLC acquired a new stake in Zymeworks during the 3rd quarter valued at approximately $1,232,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Zymeworks during the 3rd quarter worth approximately $96,000. Finally, ProShare Advisors LLC increased its position in shares of Zymeworks by 91.5% during the third quarter. ProShare Advisors LLC now owns 16,390 shares of the company’s stock worth $434,000 after buying an additional 7,833 shares during the period. Institutional investors own 92.89% of the company’s stock.

More Zymeworks News

Investors following ZYME have been watching these news items:

• Positive Sentiment: Citigroup raised its price target to $44 from $39 and maintained a Buy rating. Truist also forecast strong price appreciation, while TD Cowen lifted its target, adding to the positive analyst outlook. Truist Financial Forecasts Strong Price Appreciation for Zymeworks Zymeworks Stock Gets Price Target Boost from TD Cowen
• Positive Sentiment: Zymeworks recently reported better-than-expected earnings and reached a 52-week high, suggesting strong results had supported investor demand. Zymeworks Hits New 52-Week High After Better-Than-Expected Earnings
• Negative Sentiment: HC Wainwright cut estimates across several upcoming quarters and reduced its FY2026 EPS forecast to $1.19 from $1.51. Its FY2027 outlook shifted from expected earnings of $1.32 per share to a loss of $0.39 per share. These substantial revisions are a negative near-term signal, although the firm kept its Buy rating and $56 target. Zymeworks analyst and stock information

About Zymeworks

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.